Last Updated 2 July 2014
The Turkish pharmaceutical market is the largest in the Middle East and Africa region, the 7th largest in Europe and the 16th largest in the world. This market experienced rapid growth until 2011, although growth has slowed over the past few years. A substantial increase in national investment in healthcare and the creation of a universal health insurance system have boosted demand for healthcare services, including prescription drugs. However, a tough pricing and reimbursement environment and restrictions on market access for new imported drugs present serious challenges for multinational pharmaceutical companies (MNCs) interested in this emerging market. New cost-containment measures unveiled in November 2011 and health technology assessment measures made effective in February 2013 have added to the industry’s woes.
Market profile: Market access drivers; key opportunities and challenges; analysis of more than 40 market parameters.
Economic outlook: Global, regional, and country growth rates, 2004-2019.
Socioeconomic trends of 7 Middle East and Africa countries: Gross domestic product (GDP), nominal per capita gross national income (GNI).
Demographics of 7 Middle East and Africa countries projected to 2030: Population size; population growth rate; life expectancy at birth; median age; percentage of population aged 65 or more; percentage of population that is urban.
Healthcare investments of 7 Middle East and Africa countries: Healthcare spending as percentage of GDP (2001-2012), healthcare spending by government and private entities (2012); healthcare spending per capita (2002-2012).
Pharmaceutical markets (3 regions and 15 countries): Ranking by size; market sizes; market growth; Turkish pharmaceutical market; growth rates by volume and by sales; imported drug market share by volume and sales.
Healthcare system: Evolution of the Turkish healthcare system; impact of the Health Transformation Program; actions taken to achieve universal health insurance; reorganization of the Ministry of Health and its affiliates.
Regulation of pharmaceuticals: Key laws, regulations, and decision makers; requirements for marketing authorization; regulations for clinical trials and pharmacovigilance; harmonization activities; GMP requirements and delays; health technology assessment process; marketing authorization of imported, generic, biosimilar, and orphan drugs; promotion and advertising regulations; counterfeit drugs.
Intellectual property: Key decision makers; patent legislation; limitations of Turkish data protection provisions.
Pharmaceutical pricing: Wholesaler and pharmacy margins; use of external reference pricing as the starting point of price setting; reductions applied to external reference prices for various categories of drugs; statutory discounts levied by the social security system; recent changes to the pricing system; currency exchange issues.
Pharmaceutical reimbursement: Data requirements and procedures for admission to reimbursement; Turkish positive list; reimbursement applications; and use of internal reference pricing.
Cost containment: National pharmaceutical budget and potential penalties for overspending; price cuts; pharmacy discounts; prescribing restrictions; out-of-pocket payments; use of generics; rational drug use.
Hospital pharmacy: Public hospitals; positive list of inpatient drugs; tendering and contracts.
Pharmaceutical market: Import and export trends.
Commercial Outlook: 12 key factors to appreciate when doing business in India.
Exhibits: 25 data-rich tables and figures.